Objective-To assess the performance of the sequential combination of serum CA 125 measurement and ultrasonography in screening for ovarian cancer.
Design-The serum CA 125 concentration of each subject was determined and those with a concentration : 30 U/ml were recalled for abdominal ultrasonography. If ultrasonography gave abnormal results surgical investigation was arranged. Volunteers were followed up by annual postal questionnaire.
Setting-General practice, occupational health departments, ovarian cancer screening clinic.
Subjects-22 000 women volunteers who were postmenopausal and aged over 45 years.
Main outcome measures-Apparent sensitivity, specificity, positive predictive value, years of cancer detected.
Results-41 women had a positive screening result and were investigated surgically. 11 had ovarian cancer (true positive result) and 30 had other disorders or no abnormality (false positive result). Of the 21959 volunteers with a negative screening result, eight subsequently presented clinically with ovarian cancer (false negative result) and 21951 had not developed ovarian cancer during follow up (apparent true negative result). The screening protocol achieved a specificity of 99.9%, a positive predictive value of 26.8%, and an apparent sensitivity of 78.6% and 57.9% at one year and two year follow up respectively. The estimated number of years of cancer detected by the prevalence screen was 14 years.
Conclusions-This screening protocol is highly specific for ovarian cancer and can detect a substantial proportion ofcases at a preclinical stage. Further investigation is required to determine the effect of the screening protocol on the ratio of early to late stage disease detected and on mortality from ovarian cancer.
Introduction
The natural course of ovarian cancer is characterised by late presentation, poor response to current treatment, and a poor prognosis. Over 70% of patients have metastatic disease at the time of presentation and the overall survival rate is less than 25%. In contrast, the small proportion of patients with early stage disease at diagnosis have a relatively good prognosis with five year survival rates over 70%. That detection of early stage disease may decrease mortality for ovarian cancer has long been recognised. The identification of the CA 125 antigen' 2 and the application of real time ultrasonography to ovarian imaging3 suggested that screening for early stage ovarian cancer may be feasible.
We have reported the results of a pilot study of screening for ovarian cancer incorporating CA 125 measurement, ultrasonography, and pelvic examination. 4 The results of that study and a subsequent study using ultrasonography alone5 showed that no individual test has sufficient specificity to achieve an acceptable positive predictive value on screening postmenopausal women. Our preliminary results4 and the report of Einhom et a16 indicate that high levels of specificity can be achieved when a population of apparently healthy postmenopausal women are screened with a sequential combination of CA 125 measurement and ultrasonography. This paper reports the results of a prevalence screen of 22000 postmenopausal women to assess further the performance of CA 125 measurement and ultrasonography in screening for ovarian cancer.
Subjects and methods
Women aged over 45 years and with more than 12 months' amenorrhoea were invited to volunteer for the study by articles describing the project in the national press, leaflets distributed by the occupational health departments of companies collaborating with the project, and postal invitations from the age-sex register of 40 general practices in England, Scotland, and Wales collaborating with the project. Volunteers were eligible for the study only if they fulfilled the following criteria: (a) age 45 years or older, (b) more than one year of amenorrhoea, (c) no history of ovarian cancer, (d) no bilateral oophorectomy, (e) resident in the United Kingdom, and (f) not currently known to have active malignancy of any type. Women with a malignancy last treated more than one year before volunteering and with no evidence of recurrence were not excluded from participation. Once eligibility was established appointments were sent by post along with a detailed fact sheet describing the study, a consent form, and data sheet. Appointments were made for three months after the initial contact to avoid the screening project being used as an altemative to attending a general practice surgery. If volunteers were found to be ineligible when they attended for their registration visit they were excluded at that time. Volunteers recruited through the press attended our hospital's ovarian cancer screening clinic for registration and those recruited through occupational health departments or general practice were seen at their place of work or general practitioner's surgery respectively.
Methods
After giving informed consent volunteers completed a questionnaire and had blood taken by venepuncture for CA 125 radioimmunoassay. Blood samples were allowed to clot at room temperature and then centrifuged at 3000 rpm for 10 minutes. The serum was separated, aliquoted, and stored at -200C. The CA 125 radioimmunoassay was performed within four weeks of storing the samples according to the manufacturer's instructions (CA 125 radioimmunoassay; Abbott Laboratories, Chicago). The detection limit of the assay was 7 U/ml and the intra-assay and interassay coefficients ofvariation at 30 U/ml were 8-/5% and 9-1% respectively. A serum CA 125 concentration of 30 U/ml BMJ VOLUME 306 or more was defined as abnormal. This cut off had previously been shown to achieve high specificity in combination with ultrasonography4 and was the lowest concentration with satisfactory assay performance. If the serum CA 125 concentration was normal, volunteers were informed within six weeks of their registration visit. If the serum CA 125 level was abnormal, volunteers were recalled for real time ultrasonography.
Real time transabdominal ultrasonography was performed with a 3-5 MHz transducer either at the Royal London Hospital (by a gynaecologist with two years' ultrasound experience or a consultant radiologist) or at another hospital collaborating with the project (by a consultant radiologist). Ovarian diameter was measured in three dimensions and ovarian volume calculated by the formula for an ovoid described by Campbell et al.3 Ultrasound findings were classified as abnormal if ovarian volume was greater than 8-8 ml or ovarian echogenicity was not uniform. If the ultrasound findings were equivocal (for example, suspicious ovarian morphology but ovarian volume < 8-8 ml) ultrasonography was repeated every four to six weeks. If the ovaries could not be identified but no pelvic abnormality was apparent the ultrasound findings were classified as normal. Volunteers with an abnormal ultrasound scan result were advised to consult their general practitioner, who was informed independently of the scan report, and referral to a gynaecologist for further management was arranged. Women with a normal scan result were followed up every three months with repeat serum CA 125 measurements.
All volunteers were followed up annually after their initial visit by postal questionnaire. If no reply was received within one month further efforts to complete follow up were made by telephone, through the next of kin, and through the general practitioner. Volunteers were asked whether they had required any medical attention since the initial visit and if they had, details were obtained from the hospital or general practice.
DEFINITIONS AND STATISTICAL ANALYSIS
Specificity was defined as the percentage of volunteers without ovarian cancer who had negative results on screening. Apparent sensitivity was defined as the percentage of volunteers who had positive screening results and were known to have developed ovarian cancer after a stated length of follow up. The study design provided an apparent rather than an absolute estimate of sensitivity for two reasons. Firstly, it was not possible to establish whether women with a false negative screening result had ovarian cancer at the time of registration or had developed the disease subsequently. Secondly, it was not possible to establish the 16 13 I Serous cystadenocarcinoma 7 13 I Serous cystadenocarcinoma 12 17 I Serous cystadenocarcinoma 14 18 I Clear cell cystadenocarcinoma 9 22 *This woman declined to return for an ultrasound scan. 100% sensitivity, would require 99-6% specificity to achieve a positive predictive value of 10%. The level of specificity required to achieve a positive predictive value of 10% could be decreased by screening a population with a higher incidence of ovarian cancer, such as women with a family history of the disease. However, such an approach would include only 1-10% of ovarian cancer patients in the screened population (depending on the definition of family history). Our pilot study4 and the report by Campbell et al showed that no individual test can achieve a specificity of 99-6%. The results of this prevalence screen confirm the high specificity and positive predictive value of a sequential screening protocol incorporating CA 125 concentration as a primary test and ultrasonography as a secondary investigation.
We expected that sensitivity of the screening protocol would be more difficult to assess than specificity. Firstly, without subjecting all patients to oophorectomy it was impossible to establish with certainty which women had ovarian cancer at the time of the initial screen and which were disease free. 
screen, the distribution of the stages of ovarian cancer in the population was fixed and could not be influenced by the effectiveness or otherwise of the screening protocol. If the study population contained x early stage and y advanced stage cases of ovarian cancer the ratio of early to advanced stage disease detected would be x:y even if the screening programme was 100% sensitive. The relatively small proportion of early stage cancer detected (4/11) must be interpreted in this context and may not reflect the ability of the screening programme to detect early stage disease. If screening with CA 125 measurement and ultrasonography is an effective method of early diagnosis the ratio of early to late stage disease will be increasedat follow up screening of our population.
Despite these limitations our results confirm the suggestion from previous retrospective studies that measuring CA 125 can detect a substantial proportion of early stage ovarian cancers. CA 125 concentrations in preoperative samples from patients with clinically diagnosed ovarian cancer are raised in 500% of stage I and 90O0% of stage II cancers." Zurawski et al found serum CA 125 concentrations above 30 U/ml in six of 12 stored samples collected up to 18 months before the diagnosis of ovarian cancer, and 14 of 59 samples collected more than 60 months before diagnosis had a serum CA 125 concentration above 30 U/ml. VALUE OF SCREENING PROGRAMME An index of the potential value of a screening programme can be obtained from the years of cancer detected by a prevalence screen. The years of cancer detected estimates the average lead time before diagnosis by screening. We estimated that the lead time of our screening protocol was about 1-4 years. This estimate is based on an assumption that the age related incidence of ovarian cancer in the study population is similar to the national incidence for each age group provided by Office of Population Censuses and Surveys data. Women with a family history of ovarian cancer were probably overrepresented in the study population compared with the general population as they have a strong motivation to volunteer. As family history is an established risk factor for ovarian cancer this would tend to overestimate the duration of the CA 125 positive preclinical phase. The proportion of women with a previous hysterectomy was higher than would be expected in the general population. This factor would tend to underestimate the preclinical phase as available evidence suggests that the risk of ovarian cancer is reduced among women who have had a hysterectomy with ovarian conservation.'" " The number of years of cancer detectable by CA 125 could be greater than 1-4 years as some of the 298 volunteers with a raised CA 125 concentration but normal ultrasound appearances may develop ovarian cancer on long term follow up.
Several possible strategies exist for improving the performance of screening tests for ovarian cancer. Firstly, there is preliminary evidence that transvaginal ultrasonography can achieve greater specificity and sensitivity than abdominal scanning.'2 Secondly, Boume bronchial reactivity has been observed in research that studied regular use of (3 agonists,6 although this has not been a consistent finding.7 Secondly, a reduction in lung function was reported during a two year study of salbutamol and ipratropium bromide,8 although again this has not been found in other studies. 9 In addition, epidemiological studies have shown an increase in deaths due to asthma, which some authors have related to the use of (3 agonists,'0 and a more detailed case control study has related increased use of ( agonists to an increased risk of death from asthma." For each additional canister administered each month the odds ratio increased by 2-6. Causal relations have been suggested but the high use of 1 agonists probably merely reflects severity of asthma and that these patients with more severe asthma are at greater risk of death. Such a relation between severe asthma and the risk of death has indeed been shown in other epidemiological studies. '2 The development of a long acting ( agonist'3 for which regular use is recommended has raised some concerns. Our study compared the safety of salmeterol (50 ,ug Serevent twice daily) with that of salbutamol (200 ,ug four times a day) in a large number of patients with asthma (> 25 000). Because of the large numbers we could compare our results with events related to asthma throughout the United Kingdom. '4 15 Subjects and methods
PROTOCOL
The trial was a randomised, double blind study in parallel groups over 16 weeks. Randomisation from blocks of six was four patients allocated to salmeterol (50 ,ug, two puffs morning and bedtime and two puffs of placebo noon and early evening to retain the blinding) to two patients allocated to salbutamol (200 pg, two puffs four times a day). The general practitioners were all given prenumbered treatment packs which they gave to the patients as they were allocated the next consecutive study number. All other drugs including prophylaxis against asthma was continued throughout the study. The supervising general practitioner was asked to prescribe whatever treatment he or she considered appropriate to relieve symptoms. The trial was conducted by 3516 general practitioners and monitored by staff employed by the medical department ofAllen and Hanburys.
PATIENTS
At the first visit of the study patients with asthma were recruited by their general practitioner and randomised. After they had shown effective use of an
